🟢 Results
- Revenue:
$29.1M (+21% YoY) ✅ - HEPZATO KIT revenue:
$27.1M (+20% YoY) ✅ - CHEMOSAT revenue:
$2.0M (+18% YoY) ✅ - HEPZATO procedure volume:
+30% YoY ✅ - Gross margin:
90% (vs. 86%) ✅ - Operating cash flow:
$5.7M (positive) ⚠️ - Net income:
$2.7M (flat YoY) ⚠️ - Adjusted EBITDA:
$7.6M (-22% YoY) ⚠️ - Cash & investments:
$95.9M - Debt:
None ✅ - 2026 Revenue Guidance:
Raised to $104M–108M ✅
📌 Key Takeaways
- HEPZATO continues to gain commercial traction, with approximately 30% procedure growth and 31 active treatment centers.
- Gross margin expanded to 90%, confirming the exceptionally profitable economics of the platform.
- Management increased full-year revenue guidance, reflecting confidence in continued physician adoption and treatment-center productivity.
- Delcath is transforming HEPZATO from a single-indication product into a multi-indication liver oncology platform.
- Multiple clinical programs are progressing simultaneously, including breast cancer, colorectal cancer and combination immunotherapy strategies.
- The company remains profitable, cash-flow positive, and operates with no debt, giving it significant financial flexibility.
💬 Management
CEO Gerard Michel highlighted four major growth drivers:
- Expansion of the treatment-center network.
- Increasing physician confidence and adoption.
- Greater use of HEPZATO alongside systemic therapies.
- Development of HEPZATO into a broader liver-directed oncology platform beyond metastatic uveal melanoma.
The message from management is notably optimistic while remaining execution-focused rather than promotional.
⚠️ Watchlist
- R&D expenses increased 51% YoY, driven by additional clinical programs and hiring.
- SG&A increased 18% YoY as the commercial organization expands.
- Despite higher revenue and margins, Adjusted EBITDA declined 22% because the company is investing aggressively for future growth.
- HEPZATO still represents over 93% of revenue, making execution on this product critical.
- Future upside increasingly depends on successful expansion into additional indications, which remain in clinical development.
🎯 Bottom Line
A high-quality growth quarter.
Commercial execution remains excellent, with 21% revenue growth, 30% procedure growth, expanding margins and increased guidance confirming that HEPZATO adoption continues to accelerate.
The only real weakness is that Delcath is reinvesting aggressively into clinical development and commercialization, which temporarily pressured EBITDA and operating cash flow. Given the company's debt-free balance sheet and nearly $96M in cash, this appears to be a deliberate growth decision rather than an operational concern.
For long-term investors, the investment thesis remains intact: Delcath is evolving from a single-product company into a broader liver oncology platform, while continuing to generate positive earnings and cash flow—an uncommon combination for a company at this stage of its growth.